Compare ENIC & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENIC | ACAD |
|---|---|---|
| Founded | 2016 | 1993 |
| Country | Chile | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 4.6B |
| IPO Year | N/A | 2004 |
| Metric | ENIC | ACAD |
|---|---|---|
| Price | $3.87 | $27.15 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 21 |
| Target Price | N/A | ★ $29.24 |
| AVG Volume (30 Days) | 451.0K | ★ 1.6M |
| Earning Date | 10-29-2025 | 11-05-2025 |
| Dividend Yield | ★ 4.78% | N/A |
| EPS Growth | N/A | ★ 98.53 |
| EPS | 0.00 | ★ 1.54 |
| Revenue | ★ $3,760,459,463.00 | $1,047,118,000.00 |
| Revenue This Year | $112,978.43 | $15.16 |
| Revenue Next Year | $0.35 | $11.42 |
| P/E Ratio | $94.99 | ★ $17.36 |
| Revenue Growth | N/A | ★ 12.69 |
| 52 Week Low | $2.73 | $13.40 |
| 52 Week High | $4.05 | $27.73 |
| Indicator | ENIC | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 54.68 | 70.39 |
| Support Level | $3.81 | $26.60 |
| Resistance Level | $3.95 | $27.73 |
| Average True Range (ATR) | 0.08 | 0.89 |
| MACD | 0.01 | 0.27 |
| Stochastic Oscillator | 69.95 | 87.08 |
Enel Chile SA is an electricity utility company, which through its subsidiaries and affiliates is engaged in the generation, transmission and distribution of electricity businesses in Chile. It operates through two segments including Generation Business and Distribution and Network Business. The Generation Business Segment is comprised of a group of electricity companies that own electricity generating plants, whose energy is transmitted and distributed to end customers. The Distribution and Network Reportable Segment is comprised of a group of electricity companies operating under a public utility concession.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.